drugset / Trial / NCT05054075

Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19

NCT05054075 ↗

RandomizedCrossoverOpen-labelTreatment

Summary

The present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human SARS and COVID-19 lineage infection. The Methodology concerns in silico procedures using organic fluids from 54 bivalves (in very specific conditions) to evaluate their therapeutic effects in 6 voluntary SARS and COVID-19 infected persons with an integrative diagnosis by a computational Mora®Nova apparatus to access the basal and experimental human physiological parameters.

Timeline

Start
2021-10-01
Primary completion
2022-10
Completion
2022-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Marine liquid and fluids Unknown — —